Ensuring Regulatory Compliance During Clinical Feasibility Assessments

Introduction to Regulatory Oversight in Feasibility Planning

Feasibility assessments are not merely operational tools for site selection—they are regulatory expectations. Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), along with other global authorities, expect sponsors and CROs to conduct structured and documented feasibility assessments as part of Good Clinical Practice (GCP) compliance. Feasibility questionnaires, data validation, and documentation must align with ICH E6(R2), which emphasizes risk-based trial planning and site qualification.

Failure to perform adequate feasibility assessments has been cited in multiple inspection reports. These findings often involve:

• Inadequate documentation of site capability assessments
• Inconsistent feasibility processes across countries or trials
• Overreliance on self-reported, unvalidated data
• Absence of feasibility SOPs or version control

In this tutorial, we cover how to design and execute feasibility assessments that are fully compliant with regulatory requirements. We include real-world examples, inspection citations, and tools to ensure documentation and process rigor.

Regulatory Frameworks Governing Feasibility

The following frameworks guide regulatory expectations around feasibility in clinical development:

• ICH E6(R2) GCP Guidelines: Requires sponsors to evaluate investigator and site suitability (Section 5.6 and 5.18)
• FDA Compliance Program Manual 7348.811: Recommends inspection of sponsor site selection criteria
• EMA GCP Inspectors Working Group Reflection Paper: Highlights deficiencies in feasibility documentation as a key inspection risk
• MHRA GCP Guide: Emphasizes robust feasibility as part of trial start-up planning

These guidelines stress not only the presence of a feasibility assessment but also its documentation, validation, and consistency across clinical programs.

Minimum Documentation Requirements

A regulatory-compliant feasibility package should include:

For example, if a site claims they can enroll 40 patients with a rare genetic disorder, the sponsor must retain justification such as regional disease prevalence reports, or prior enrollment records validated by registry data like Japan’s RCT Portal.

Common Regulatory Audit Findings

Below are real-world FDA and EMA audit observations related to feasibility:

• “The sponsor did not document the criteria used for selecting investigator sites.”
• “Feasibility assessments lacked supporting data to justify projected recruitment timelines.”
• “No evidence that sponsor reviewed investigator GCP training prior to site initiation.”
• “Feasibility SOP was outdated and inconsistently applied across regions.”

These findings not only delay trial progression but can result in critical or major inspection outcomes that require CAPA submission and re-inspection.

Role of Feasibility SOPs and Governance

Sponsors must implement and follow a standardized feasibility SOP that defines:

• Responsibilities of feasibility managers, CRAs, and medical reviewers
• Timing of feasibility (pre-IRB, pre-contract)
• Use of digital platforms and validation of e-questionnaires
• Criteria for scoring and risk ranking of sites
• Filing of completed questionnaires in eTMF

The SOP should also include annexures for therapeutic-specific feasibility checklists (e.g., oncology, CNS, vaccines) and region-specific adaptations (e.g., India, China, EU).

Governance committees should oversee feasibility quality by conducting:

• Spot audits of feasibility responses
• Review of enrollment accuracy versus feasibility predictions
• Corrective Action Plans (CAPA) for overestimated sites

Data Integrity and Electronic Feasibility Tools

When using digital platforms, the feasibility process must maintain data integrity standards in line with 21 CFR Part 11 and Annex 11. This includes:

• Audit trails for each change in survey response
• Unique user access for PIs and staff completing the forms
• Electronic signature certification and locking of final entries
• Data backup and disaster recovery plans for e-feasibility tools

For example, if a feasibility platform allows sites to revise their estimated enrollment, the system must log who made the change, when, and why—ensuring full traceability.

Cross-Verification with Source Systems

Feasibility responses must be cross-verified with:

• Clinical Trial Management Systems (CTMS): Prior performance data
• eTMF: GCP training records, signed PI forms
• Public registries: Recruitment metrics from prior trials

This prevents sites from overstating capacity or infrastructure. Some sponsors use feasibility scoring dashboards that auto-rank sites based on enrollment history, deviation rates, and startup timelines—integrated with CTMS and analytics tools.

Regulatory Expectations by Region

Global feasibility assessments must incorporate branching logic or country-specific forms to meet these requirements.

Checklist for Regulatory-Compliant Feasibility

• Completed and signed questionnaire by PI or designee
• Supporting documents for patient estimates and equipment
• GCP certification and CVs reviewed
• Feasibility scoring or risk ranking documented
• SOP version used is up to date and applied consistently
• All documents filed in audit-ready location (eTMF)

Conclusion

Feasibility assessments are not just an operational exercise—they are a regulatory obligation. Sponsors and CROs must ensure their feasibility process is governed by SOPs, aligned with global regulations, and fully documented. Leveraging digital tools, cross-verifying with historical data, and training teams in compliance best practices is essential. With regulatory inspections becoming more rigorous, proper feasibility assessments reduce trial risk, improve start-up timelines, and enhance overall study quality.

Understanding Regulatory Considerations During Feasibility Assessments

Feasibility assessments are a critical step in clinical trial start-up, allowing sponsors and CROs to evaluate whether potential sites can successfully execute a protocol. However, beyond site infrastructure, patient pools, and investigator experience, regulatory compliance is equally vital. Inadequate attention to regulatory requirements during feasibility can lead to delays, rejections, or audit findings. This guide outlines the essential regulatory elements that must be reviewed as part of every feasibility evaluation.

The Role of Regulatory Compliance in Feasibility

Clinical trial regulations set the foundation for ethical conduct, subject protection, and data integrity. Regulatory oversight agencies—such as the USFDA, EMA, and CDSCO—require documented evidence that investigational sites are capable of meeting regulatory standards before approval.

During feasibility, sponsors must verify that a site is not only suitable for operations but also aligns with regional and international guidelines like ICH-GCP. Regulatory gaps at this stage can lead to costly start-up delays or compliance issues post-initiation.

Key Regulatory Checks During Feasibility Assessments

1. Licensing and Accreditation of Site and Investigators

• Principal Investigator (PI) must have valid medical licensure for the country of operation
• Site should be registered with national regulatory authorities (where applicable)
• Verify any historical suspensions, sanctions, or non-compliance records

2. IRB/EC Review Capabilities

• Confirm whether the site has access to a functioning Institutional Review Board or Ethics Committee
• Assess average timelines for initial and continuing review
• Check if the EC complies with national GCP regulations and maintains adequate documentation

3. Informed Consent Process Oversight

• Ensure that informed consent SOPs align with Pharma SOP documentation
• Review the site’s history with vulnerable populations, if applicable
• Determine if translations and local adaptations are supported by EC

4. Regulatory Submissions and Approvals

• Check site familiarity with regulatory submission procedures for CTAs or INDs
• Review documentation timelines from past trials (e.g., CDSCO SUGAM Portal, EMA Clinical Trial Portal)
• Ensure readiness to handle amendments, notifications, and queries during the trial

5. GCP Training and Documentation

• Confirm that all site staff have completed recent GCP training (within 2 years)
• Request training certificates or rosters for documentation
• Evaluate understanding of ICH E6 (R2) and relevant national adaptations

Country-Specific Regulatory Expectations

Each region imposes specific requirements during feasibility. For example:

• India (CDSCO): Sites must be registered with the CDSCO and ECs accredited under NABH or equivalent bodies
• USA (FDA): Requires Form 1572 and Investigator CVs submitted to the IND file
• EU (EMA): Site details must be entered in the CTIS for each trial
• UK (MHRA): Requires pre-approval of site and PI in trial notification

Understanding these differences ensures proper selection and preparedness of sites globally.

Documentation for the Trial Master File (TMF)

As per ICH-GCP and StabilityStudies.in recommendations, feasibility documentation with regulatory components must be maintained in the TMF, including:

• Signed feasibility questionnaires with regulatory declarations
• Copies of licenses, CVs, and GCP training certificates
• EC registration documents
• Feasibility decision-making justifications

Creating a Regulatory Feasibility Checklist

Sponsors should include a dedicated regulatory section in their feasibility checklist covering:

• PI licensing status and experience
• EC operational capability and accreditation
• Historical compliance data (e.g., audit findings, inspection outcomes)
• Submission readiness and GCP compliance

This can be developed into a site scorecard and integrated with the overall site qualification process.

Common Pitfalls and How to Avoid Them

• Assuming EC availability: Always confirm the EC is currently functioning and accepting reviews
• Overlooking licensing renewals: PI or staff may have expired registrations
• Inconsistent GCP records: Ensure centralized verification of training validity
• Lack of audit documentation: Request recent inspection reports, especially if conducted by agencies like TGA or ANVISA

Integrating with Site Feasibility SOPs

Your feasibility SOP should clearly assign responsibilities to regulatory affairs or clinical operations teams for verifying these elements. Regulatory feasibility should be completed before final site approval and revisited during site initiation.

Conclusion

Regulatory considerations are a foundational component of feasibility assessments. They ensure that sites are compliant, inspection-ready, and capable of meeting trial expectations. By embedding regulatory checks early in the feasibility process, sponsors can avoid costly delays and ensure seamless clinical trial execution with full compliance to global standards.

Overcoming Challenges in Global Site Feasibility Assessments

Global site feasibility assessments are essential for selecting suitable clinical trial sites across diverse geographical regions. However, expanding feasibility efforts internationally introduces significant complexities. Sponsors and CROs must navigate regulatory differences, operational hurdles, and cultural nuances while ensuring consistent, quality-driven site selection. This tutorial explores the key challenges in global feasibility and how to mitigate them using standardized processes and informed strategies.

Why Global Feasibility Is More Complex Than Domestic

Unlike single-country feasibility efforts, global feasibility assessments must account for:

• Multiple regulatory environments
• Variations in site infrastructure and SOPs
• Different clinical practices and care standards
• Time zone and language barriers
• Diverse patient populations and recruitment timelines

These factors make data harmonization and feasibility comparisons more difficult, leading to increased trial start-up timelines and variability in study performance.

Major Challenges in Global Site Feasibility Assessments

1. Regulatory Variability Across Countries

• Every region has unique ethics and regulatory approval pathways
• Timelines and documentation requirements vary significantly
• For example, EMA timelines differ widely from CDSCO in India

2. Inconsistent Site Infrastructure and Resources

• Some regions may lack equipment, staff, or digital capabilities
• Site readiness varies by country and sponsor support systems
• Reliability of courier services and sample storage can also impact feasibility

3. Language and Cultural Barriers

• Feasibility forms may need translation and localization
• Misinterpretation of study requirements due to language gaps
• Varying perceptions of clinical research ethics or compensation models

4. Data Privacy and Protection Compliance

• GDPR (EU), HIPAA (USA), and country-specific laws impose different data handling rules
• Compliance requires adapting feasibility forms and data collection methods
• Feasibility systems must ensure encrypted and permissioned access

5. Limited Access to Historical Site Performance

• Global sites may lack a centralized registry for recruitment metrics
• Sponsors must rely on investigator self-reports or use third-party databases
• Site performance may be over- or under-stated without verification

Strategies to Overcome Global Feasibility Challenges

1. Use Standardized Feasibility Templates with Localization

Design standardized templates aligned with protocol needs, but allow localized versions to meet regulatory or language requirements. You can use formats from Pharma SOP templates and adjust based on region.

2. Implement Global CTMS and Dashboards

Use CTMS systems with region-specific fields and dashboards to track site-specific timelines, EC submissions, and investigator qualifications. Integration helps harmonize site comparison across countries.

3. Conduct Remote and On-Site Feasibility Checks

Leverage a hybrid approach of remote feasibility interviews and in-country monitoring visits. Include CRA input from regional teams familiar with local conditions.

4. Train Regional Teams in Feasibility SOPs

Conduct dedicated training for regional staff on global feasibility expectations, sponsor standards, and how to manage cultural sensitivities. Use checklists to ensure consistency across feasibility assessments.

5. Score Sites Using a Weighted, Data-Driven Model

• Assign scores to key feasibility criteria:
• Startup Timelines (30%)
• Infrastructure and Equipment (25%)
• Investigator and Team Experience (20%)
• Past Performance Data (15%)
• Compliance History (10%)
• Rank sites globally for strategic selection

Technology Enablers for Global Feasibility

• REDCap for multilingual feasibility data collection
• Global CTMS systems with EDC and eTMF integrations
• Feasibility tracker templates using Excel or Power BI
• AI-powered feasibility analysis tools

Several tools also offer compliance with regional data protection policies and can be reviewed via portals like StabilityStudies.in.

Documenting and Auditing Global Feasibility Efforts

As per USFDA and other regulators, site feasibility documentation must be audit-ready and preserved in the Trial Master File (TMF). Sponsors should ensure that feasibility outcomes are traceable and decisions justifiable.

Conclusion

Global site feasibility assessments present several operational and regulatory challenges. By standardizing processes, leveraging digital tools, and empowering regional teams, sponsors and CROs can overcome barriers and select sites that are not just eligible—but optimally equipped—for clinical trial success. A structured, transparent feasibility process ensures quality, speed, and global compliance.